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ABSTRACT 
The transcription factors STAT1 and STAT3 appear to play opposite roles in 
tumorigenesis. While STAT3 promotes cell survival/proliferation, motility and immune 
tolerance and is considered as an oncogene, STAT1 mostly triggers anti-proliferative 
and pro-apoptotic responses while enhancing anti-tumour immunity. Despite being 
activated downstream of common cytokine and growth factor receptors, their activation 
is reciprocally regulated and perturbation in their balanced expression or 
phosphorylation levels may re-direct cytokine/growth factor signals from proliferative 
to apoptotic, or from inflammatory to anti-inflammatory. Here we review the functional 
canonical and non canonical effects of STAT1 and STAT3 activation in tumorigenesis 
and their potential cross-regulation mechanisms. 
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1. Introduction. 
 Cross-talk between signaling pathways determines how a cell integrates the 
environmental signals received, ultimately translating them in transcriptional regulation 
of specific sets of genes. Transcription factors belonging to the Signal Transducer and 
Activator of Transcription family (STATs), being able to detect a variety of signals at 
the inner cell membrane and to transduce them to the nucleus directly affecting gene 
regulation, are ideally suited to play a central role in orchestrating the outcome of this 
cross-talk.1 Indeed, despite an intriguing convergence of distinct cytokine and growth 
factor receptors on STAT1 and STAT3 signaling (e.g. type I and II Interferons (IFNs), 
IL-6-type cytokines, growth factors such as EGF and PDGF), these soluble mediators 
elicit specific patterns and duration of STATs activation, resulting in distinct and often 
opposing effects on target cells.2 While STATs activation is typically fast but transient, 
due to specific negative feedback mechanisms, aberrant activation often leads to 
pathological conditions such as chronic inflammation, defective immune responses or 
cancer. Here, we present what is known about the actions of STAT1 and STAT3 in 
oncogenesis and finally discuss data suggesting reciprocal cross-regulation, likely to 
impact on different stages of tumour biology. 
STAT1 is a central mediator of both type I (alpha and beta) and type II (gamma) 
IFNs,3 which are involved in cell growth regulation and antiviral and immune defense. 
IFN-gamma (IFNγ) mainly triggers prolonged STAT1 activation that induces gene 
expression by binding to gamma-activated sequences (GAS). In contrast, type I IFNs 
activate both STAT1 and STAT2 triggering the formation of the ISGF3 transcriptional 
complex. Both IFN types can in addition activate STAT3, albeit to a lesser extent/more 
transiently.2  
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The IL-6 family of cytokines acts instead through homo- or hetero-dimerization 
of a common signal transduction subunit, gp130, with other specific receptors such as 
the LIFR. This activated receptor complex triggers tyrosine phosphorylation of 
STAT1/STAT3, which is either prolonged (STAT3) or transient (STAT1).4 Once 
phosphorylated, these two factors can bind to similar cognate sites both as homo- and as 
hetero-dimers, at least in vitro. However, the repertoire of target genes is mostly 
distinct, suggesting the need for specific co-factors for in vivo binding.2 STAT1 and 
STAT3 are thought to play opposite roles in tumorigenesis. STAT1 exerts a complex 
array of functions on both tumour cells and the immune system and is usually 
considered as a tumour suppressor.5 In contrast, STAT3 is considered as an oncogene, 
being constitutively active in nearly 70% of solid and hematological tumours, which 
often become dependent on its activity for their growth and survival.6 Accordingly, 
STAT3 activation can be elicited by a number of oncogenes (e.g. v-Src, v-Fps, v-Sis, 
Met, polyoma middle T antigen) in addition to the above listed cytokines and growth 
factors.  
Moreover, over-expression of its constitutively active form, STAT3C, is sufficient to 
transform already immortalized fibroblasts and other non-malignant cell types such as 
breast and prostate epithelial cell lines (reviewed in ref. 6). Of note, the continued 
activity of the STAT3C artificial mutant was shown to be at least partly due to slower 
dephosphorylation rates and increased DNA binding affinity, resulting in prolonged 
activation and elevated expression of STAT3 target genes.7,8 
Both STAT1 and STAT3 can exert their opposing effects on tumorigenesis 
either directly, through transcriptional regulation of target genes in the neoplastic cell, 
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or indirectly, by modulating tumour angiogenesis, tissue invasion or the anti-tumour 
immune response.  
 
2.1. Direct effects of STAT1 and STAT3 activity on tumour growth 
STAT1 and STAT3 can directly activate targets with functions on proliferation 
and apoptosis. STAT1 typically promotes apoptosis by inducing the expression of 
members of the cell surface death receptor family and their ligands, in addition to 
caspases and iNOS; it can also repress the p53-inhibitor Mdm2 and act as a p53 co-
activator.6,9,10 Additionally, STAT1 negatively regulates the cell cycle inducing the 
expression of IFITM1, the CDK inhibitors p21waf/cip1 and p27Kip1 and the G1/S phase 
blocker KLF4.6 Conversely, STAT1 activation inhibits the expression of several cyclins 
and of the oncogenes c-Myc and HER-2.6,11   
 In contrast, STAT3 constitutive activity is essential for proliferation and/or 
survival of many established or primary tumour cells, and its inhibition impairs tumour 
growth.6 STAT3 expression signature, although different in distinct tumour contexts, is 
indeed consistent with tumour cell growth and survival. Among STAT3 target genes are 
anti-apoptotic proteins, such as survivin and members of the Bcl family (e.g. Bcl-XL, 
Bcl-2 and Mcl1 - myeloid cell leukemia sequence 1) and proteins involved in 
proliferation and cell cycle progression such as cyclin D1, c-Myc and pim-1/2.6,12,13 
STAT3 can also inhibit apoptosis by suppressing Fas transcription and, in the mouse, 
p53 expression. It must be noted, however, that under physiological conditions STAT3 
may act as an inducer of cell death. In particular, STAT3 is required for epithelial cell 
death during mammary gland involution, specifically triggering lysosome-mediated cell 
death.14 
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Consistently with its predominant anti-apoptotic role in cancer cells, STAT3 can 
confer resistance to chemotherapeutic drugs in several tumours. For example, 
doxorubicin activates STAT3 in a metastatic subline of breast cancer cells, suggesting 
that STAT3-mediated anti-apoptotic effects may represent one of the protection 
mechanisms activated in response to chemotherapeutic drugs.15 Indeed, interference 
with STAT3 activity sensitizes cells to doxorubicin-, taxol- or adriamycine-induced 
apoptosis in highly metastatic breast cancer cell lines,15 suggesting that STAT3 
inhibition coupled to chemotherapeutic treatment might be a valid approach to cancer 
therapy. 
In contrast with its prevalent pro-apoptotic role, STAT1 was recently shown to 
correlate also with improved resistance to chemotherapeutic drugs, as in the case of 
ovarian cancer and of cutaneous T-cell lymphoma.16,17 
 
2.2. STAT3 can enhance survival and proliferation by acting on tumour glucose 
metabolism. 
STAT3 is essential for tumour transformation downstream of several oncogenes 
including Src18 and Ras.19 Interestingly, while Src induces STAT3 tyrosine 
phosphorylation and transcriptional activity, Ras elicits phosphorylation of STAT3 on 
serine 727, recently shown to be required for its localization to mitochondria. In turn, 
mitochondrial STAT3 enhances the respiratory chain activity under normal or Ras-
transformed conditions, thus supporting Ras oncogenic transformation.19,20 In contrast, 
we have recently shown that constitutively active STAT3 is part of the complex 
signaling network that shapes the metabolic phenotype of tumour cells and that 
includes, among others, the PI3K pathway and the transcription factors hypoxia-
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inducible factor (HIF), p53, Myc and NF-κB.21,22 Indeed, constitutively active STAT3 
acts as a master regulator of cell metabolism, inducing aerobic glycolysis via HIF-1α) 
transcriptional induction and down-regulating mitochondrial activity in a HIF-1α-
independent way both in primary fibroblasts and in STAT3-dependent tumour cell 
lines.23 Cells are thus protected from apoptosis and senescence while becoming highly 
sensitive to glucose deprivation. This metabolic switch, known as the Warburg effect, is 
shared by most cancer cells and is believed to lend a metabolic advantage to highly 
proliferating cells when nutrient supply is not limiting, as it favours the synthesis of 
essential cellular components required for fast cell duplication.24 In addition, glycolysis 
generates ATP at a higher rate than oxidative phosphorylation and this is an 
advantageous feature for tumor cells as long as glucose supplies are not limited. 
Aerobic glycolysis and reduced mitochondrial respiration are important components of 
STAT3-mediated oncogenesis, as STAT3 inhibition in tumour cell lines down-regulates 
glycolysis and up-regulates mitochondrial activity prior to leading to growth arrest and 
cell death.23 This novel metabolic role is likely at the core of the addiction to STAT3 
shown by so many biologically different tumours, and may provide further selective 
advantages in the hypoxic environment of solid tumours as well as of the stem cell 
niche. Of note, IFN-γ-induced STAT1 activation was recently shown to negatively 
regulate HIF-1α-dependent transcription in human glioblastoma cells lines, once more 
highlighting the opposite effects of STAT1 and STAT3 in tumors.25  
Thus, two distinct forms of "active" STAT3 exist: i) tyrosine phosphorylated 
STAT3, which is nuclear and transcriptionally active and ii) serine phosphorylated 
STAT3, which is localized to mitochondria and transcriptionally inactive. Although 
regulated downstream of different signals under distinct physiological or pathological 
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conditions, and eliciting different effects on cellular respiration, both forms finally 
converge to enhance cell survival and protection from apoptosis via specific regulation 
of mitochondrial functions.26 
 
2.3. Both STAT1 and STAT3 can support the expansion of Cancer Stem Cells. 
  Cancer Stem Cells (CSCs), or tumour initiating cells, are a small population of 
slowly, asymmetrically dividing cells, which are resistant to chemotherapy and thought 
to be responsible for recurrence. STAT3, prominently involved in maintaining 
undifferentiated mouse embryonic stem cells, also plays a role in the maintainance of 
CSCs. Indeed, in Head and Neck Squamous Cell Carcinoma (HNSCC) cells STAT3 
phosphorylation levels correlate with high tumorigenicity and the expression of stem 
cell markers.27 STAT3 activity is also crucial for neurosphere formation in 
glioblastoma,28 and for tumorsphere formation in human colon cell lines.29 STAT3 
inhibition in glioblastoma and HNSCC cells leads to sensitization to chemotherapeutic 
treatment,27,28 a potential strategy for CSCs eradication. Additionally, several data sets 
point to a role for STAT3 in breast CSCs. STAT3 is required for the viability of the 
stem-like side population of MCF-7 cells.30 Moreover, autocrine IL-6 signaling sustains 
the aggressiveness of hypoxia-selected MCF-7 cells and enhances breast CSCs 
malignancy in several models.31 Finally, the stem cell-like subpopulation from human 
breast tumours shows high STAT3 activation and this drives STAT3 phosphorylation in 
other tumour cells via secretion of IL-6,32 and IL-6 drives the conversion of non-stem 
cancer cells into CSCs in human breast tumours and in a prostate cell line.33 
 The data correlating CSCs with STAT1 are more conflicting. In a model of 
oncogene-driven leukemia, the expansion potential of leukemia initiating cells is 
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severely reduced in the absence of STAT1,34 and  STAT1 deficient mice are partially 
protected from leukemia development.35 In contrast, IFNα treatment triggers 
proliferative reactivation of dormant hematopoietic stem cells (HSCs).36 This process 
requires STAT1 activity and sensitizes HSCs to the chemotherapeutic agent 5-fluoro-
uracil, providing a potential mechanism for the so far unexplained clinical effects of 
IFNα on leukemic cells. 
 
3. STAT3 enhances epithelial to mesenchymal transition and cell migration.  
Epithelial-mesenchymal transition (EMT), during which epithelial cells lose 
cell-cell adherence and acquire mesenchymal properties leading to migration, tissue 
invasion and metastasis, has been linked to the progression of epithelial tumours.37 
STAT3 activity is required for EMT during gastrulation in zebrafish via the regulation 
of the breast-cancer-associated zinc transporter LIV1.38 More recent data suggest a 
direct link between STAT3 and EMT. Twist1, a major player in EMT, is a direct 
STAT3 target, and STAT3-mediated Twist-1 induction is involved in EGF-triggered 
EMT of cancer cells.6,39 Moreover, IL-6 induces EMT in the human breast cancer cell 
line MCF-7, and constitutive Twist1 expression triggers aberrant IL-6 production and 
STAT3 activation, suggesting a positive autocrine loop.40 Finally, we have recently 
shown that the tensin family member Cten, known to play a role in invasive cancer and 
to mediate EGF-induced migration, is a novel STAT3 target that contributes to 
disruption of cell-cell contacts and enhances migration and invasion in a model of 
HER2-mediated breast cancer.41 
STAT3 can regulate cell movement also independently of EMT, as suggested by 
the observation that STAT3 conditional disruption in keratinocytes results in impaired 
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migration and wound healing in response to EGF, TGF-α, HGF and IL-6. Moreover, 
STAT3 was shown to contribute to the disruption of epithelial adhesion and polarity 
downstream of ErbB2-Integrin β4 signaling (reviewed in ref. 6).  
STAT3 may regulate cell motility also via non-nuclear functions. For example, 
phosphorylated STAT3 was reported to localize to focal adhesions in ovarian carcinoma 
cells and to interact with active focal adhesion kinase and paxillin, correlating with cell 
motility and aggressiveness.42 Interestingly, we could observe a similar localization in 
cells derived from MMTV-NeuT tumours expressing constitutively active STAT3.41 In 
addition, non-phosphorylated STAT3 can interact with the microtubule-destabilizing 
protein stathmin, resulting in enhanced polymerization and cell migration.43 
 
4. Effects of STAT1 and STAT3 activity on tumour angiogenesis and metastasis 
 Both STAT1 and STAT3 can also indirectly control tumour growth by regulating 
angiogenesis in opposite ways. STAT1 acts as a negative regulator of tumour 
angiogenesis and, hence, tumour growth and metastasis by suppressing VEGF 
biological activity and the expression of pro-angiogenic FGF-β, while inducing the 
antiangiogenic chemokine IP-10 (CXCL10).6 The IFNγ/STAT1 pathway also 
counteracts pancreatic tumour growth by inhibiting the pro-tumoral fibrosis due to 
overproduction of extra-cellular matrix proteins by pancreatic stellate cells.44 Similarly, 
STAT1-mediated inhibition of the urokinase-type plasminogen activator (uPA) gene 
expression in breast cancer plays an antimetastatic role.45 
In contrast, STAT3 enhances angiogenesis by mediating both VEGF expression 
and signaling, either directly or via HIF-1α.6 In addition, STAT3 can also enhance 
tissue invasion and metastasis by inducing members of the matrix-metalloproteinases 
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family of proteins including MMP-9 and MMP-2, both of which are instead 
downregulated by STAT1.6,46 Moreover, STAT3 contributes to initiation and 
progression of pancreatic ductal adenocarcinoma at least partly by upregulating MMP7, 
whose serum levels are predictive of metastatic disease.47 
 
5. Both STAT1 and STAT3 are important regulators of anti-tumour immune 
responses.  
Despite some contrasting observations, most data point to STAT1 as an important 
check-point to control tumour development via activation of the immune system, acting 
both on tumour and immune cells. Both type I and type II IFNs are crucial in the 
phenomenon formerly known as immunosurveillance and now defined by the broader 
concept of cancer immunoediting.48 Indeed, several human melanomas and squamous-
cell carcinomas are able to bypass the immune system control by downregulating 
STAT1 expression.6 
Activation of the IFNγ/STAT1/IRF1 axis favours processing and presentation of tumour 
antigens, in association with MHC class I or class II molecules.6 This function is 
mediated by direct regulation of MHC class I antigens expression, of the antigen 
processing-associated transporters (TAP)1 and TAP2, and of LMP2 and LMP7.6,49,50 
Moreover, the expression of the MHC class II transactivator CIITA, a coactivator 
essential for MHC class II transcription that is reduced in many tumours, is STAT1-
dependent.6 Defective antigen presentation due to impaired IFNγ/STAT1 signaling, 
including STAT1 gene promoter methylation or de-acetylation, is a frequently observed 
strategy to escape immunosurveillance.6 These tumours become resistant to the direct 
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anti-proliferative/pro-apoptotic effect of IFNγ released by T and Natural Killer (NK) 
cells and fail to overexpress MHC class I in response to IFNγ, thus becoming unable to 
display tumour associated antigens to effector CD8+ T cells. Of note, intra-tumoral T 
cells, nuclear STAT1 and strong MHC class I expression correlate with improved 
survival and identify patients that may benefit from immunotherapy in colorectal 
cancer.49 In the same vein, STAT1 is one out of five genes predictive of relapse-free and 
overall survival in Non Small Cell Lung Cancer (NSCLC),51 and its activation in 
immune cells predicts a favourable outcome correlating with activation of the immune 
response in melanoma.52 Indeed, down-regulation of the IFN signaling pathway can also 
occur in the immune cells, an alternative strategy to escape immunosurveillance 
observed in T lymphocytes from patients with metastatic melanoma.53 Thus, defects in 
IFNγ/STAT1 signaling represent novel, dominant mechanisms of immune dysfunction 
in cancer. These findings might be exploited to design therapies to counteract immune 
dysfunction and improve cancer immunotherapy. It must however be borne in mind that 
STAT1 activation can sometimes inhibit rather than favour anti-tumour immune 
responses. In tumour-associated macrophages (TAMs), for example, STAT1 regulates 
the expression of arginase and NO, which in turn suppress T cell-mediated immune 
responses and induce T cell apoptosis, respectively, correlating with an adverse 
outcome.54,55 In addition, STAT1 can induce indoleamine 2,3-dioxygenase, an enzyme 
over-expressed in many cancers that blocks T lymphocytes activation,56 it can suppress 
the IL-12-mediated anti-tumour CTL activity,57 and its expression increases in late stage 
melanoma.58 
STAT1 activity has also an ambiguous role in mammary carcinoma, where it represents 
a positive prognostic factor when expressed alone,59 but not when associated with 
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phospho-STAT3.60 Moreover, STAT1 co-expression with CD74 and Mx1 or with 
MUC1, respectively, identifies most aggressive triple negative breast tumours,61 
correlating with poor prognosis.62  
In contrast to STAT1, STAT3 has a key role in mediating tumour immune-evasion. 
STAT3 constitutive activity in tumour cells is indeed able to inhibit the maturation of 
antigen presenting cells (APCs), including dendritic cells (DC) and macrophages, at 
least partly through the production of soluble anergyzing factors such as VEGF and IL-
10 and the reduced secretion of pro-inflammatory mediators.13 This inhibitory effect 
occurs via STAT3 activation in APCs, which is in turn responsible for impaired DC-
mediated induction of T cell responses. Recently, tumour-derived exosome-associated 
Hsp72 was shown to induce STAT3 activity in myeloid-derived suppressor cells 
(MDSC) in a TLR2/MyD88-dependent manner.63 STAT3 activation in TAMs triggers a 
switch between the production of the anti- and pro-tumorigenic cytokines IL-12 or IL-
23 respectively by blocking NF-κB-dependent IL-12 production while inducing IL-23 
transcription.64 IL-23 in turn triggers the expansion of pro-inflammatory Th17 cells, 
which require STAT3 for their differentiation and activity, and stimulates the 
production of IL-10 by regulatory T cells, further inhibiting the immune response. 
Recently, constitutively active STAT3 in growing tumours and tumour-infiltrating 
immune cells was shown to facilitate NF-κB binding to genes that are important for 
tumour growth, which contain both NF-κB and STAT3 DNA-binding site(s), while 
inhibiting its binding to Th1 immunostimulatory genes, only carrying NF-κB responsive 
elements.65 
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Indeed, STAT3 blockade in tumour cells increases the production of 
chemoattractants and the infiltration of immune cells, resulting in macrophage-mediated 
cytostatic activity.13 On the other hand, inhibition of STAT3 in macrophages could 
induce an anti-tumour immune response in a rat model of breast cancer,13,64 and in vivo 
deletion of STAT3 in hematopoietic precursor cells resulted in enhanced anti-tumour 
activity triggered by DC, T cell, NK cells and neutrophils, correlating with a reduction 
of regulatory T cells.13 
 
6. STAT3 and tumour-associated inflammation 
Tumour-associated inflammation has a crucial role in both initiation and 
progression of many malignancies.66 Indeed, chronic inflammatory conditions such as 
inflammatory bowel disease, hepatitis or pancreatitis are well known cancer 
predisposing factors. Infiltrating immune cells promote chronic inflammation and 
sustain growth and survival of pre-malignant cells by triggering continuous production 
of pro-inflammatory cytokines like IL-6. High IL-6 levels are often found in the serum 
of human patients with colon, breast, prostate, lung, ovary and liver cancer.67 Indeed, 
STAT3 has emerged as a key player in tumour-associated inflammation. Active STAT3 
is often found at the invasive edge of tumours, adjacent to inflammatory cells, 
suggesting a role in the crosstalk between immune and tumour cells.68 Moreover, mice 
lacking STAT3 in the intestinal epithelial cells (IECs) are more resistant to the onset of 
AOM + DSS-induced colon carcinomas, a model of colitis-associated 
tumorigenesis.69,70 IL-6 produced by myeloid cells infiltrating the pre-cancerous tissue 
activates STAT3 in IECs, thus triggering survival and proliferation of pre-malignant 
cells and supporting a persistent inflammatory microenvironment that later will also 
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sustain STAT3-dependent tumour growth. However, we have recently observed that 
ablation of Stat3 in IECs, although reducing early adenomas multiplicity, promotes 
tumour progression at later stages, leading to invasive carcinomas and significantly 
shortened lifespan.71 These data suggest specific functions according to different 
tumoral contexts, which need to be carefully assessed before resorting to anti-STAT3 
therapeutic approaches. 
On the other hand, STAT3 has been shown to be essential for the initiation and 
progression of pancreatic ductal adenocarcinomas.47,72 STAT3 deletion in pancreatic 
epithelial cells severely affects tumour formation in the KrasG12D mouse model of 
pancreatic intraepithelial neoplasia.47 In this context, STAT3 mediates the conversion of 
pancreatic epithelial cells to progenitor-like cells, more susceptible to Kras-mediated 
transformation, upon cerulein-induced pancreatitis. Furthermore, STAT3 orchestrates 
tumour-associated inflammation by regulating the production of chemokines able to 
attract IL-6 and IL-11-producing immune cells, which in turn sustain STAT3 activity.  
 
7. STAT1:STAT3 cross-regulation. 
 As discussed above and depicted in Fig. 1, with some exceptions STAT1 and 
STAT3 play opposing roles in proliferation, apoptotic death, inflammatory and anti-
tumour immune responses. In addition, studies on STAT-deficient cells/animals have 
revealed the existence of reciprocal STAT1:STAT3 regulatory mechanisms (reviewed 
in ref. 2). Indeed, STAT3 has recently emerged as a key player in holding the balance 
not only between the reciprocal STAT3 versus STAT1 activation levels but also 
between the STAT versus the MAPK branches of cytokine signaling. STAT3-/- cells 
display prolonged STAT1 and MAPK activation downstream of several IL-6 family 
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cytokines both in vitro and in vivo.73,74 As a consequence, IL-6 induces in these cells an 
IFNγ-like response,74 and triggers prolonged induction of immediate early genes such as 
cFos and Egr1.75 Interestingly, we have recently shown that phosphorylated STAT1 
binds to the promoters of the IFN-responsive IRF-1 as well as of the Fos and Egr1 
immediate early genes, mediating their aberrant transcriptional activation in the absence 
of STAT3.75 Increased and prolonged phosphorylation of STAT1 in response to gp130 
cytokines occurs in several systems upon STAT3 gene inactivation (reviewed in ref. 2), 
suggesting that in normal cells one of the functions of STAT3 in response to IL-6 is to 
down-regulate STAT1 activity. In this vein, STAT1 expression was recently shown to 
be required for cell death induced by treatment with the JAK1 inhibitor AG490, 
believed to act by abolishing  STAT3 activation,76 and by a STAT3-decoy 
oligonucleotide.77 Of note however, Lui et al. have shown STAT1-independent effects 
of the same decoy.78 Similarly, IFNγ and IFNα trigger proliferative responses 
correlating with STAT3-mediated transcription in STAT1-deficient bone-marrow-
derived macrophages, T lymphocytes or MEFs.6 Thus, the relative abundance of 
STAT3 or STAT1 may play a role in determining their activation levels in response to 
activating stimuli. This may be relevant for the development and growth of tumours in 
the presence of specific tumour microenvironments, where different cytokine/growth 
factor combinations can modulate the relative levels of STAT1 and STAT3, resulting in 
their differential activation. Interestingly, many of the inflammatory mediators produced 
by cancer cells upon STAT3 inactivation are typical STAT1 targets (e.g. CXCL10, 
CCL5, ICAM1).  
It is thus tempting to speculate that interfering with the activation of either factor 
in tumours may result in activation or re-activation of the other. Thus, care should be 
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taken to plan therapeutic intervention using compounds that could unbalance finely 
tuned equilibria between STAT1 and STAT3. At the same time, the possibility to 
activate a specific STAT pathway by interfering with the other may under specific 
conditions provide unique therapeutic opportunities. For example, we have recently 
shown that interference with STAT3 activity in IFNγ-resistant human T lymphoma cells 
enhances pro-apoptotic responses to IFNγ while making cells sensitive to IL-6, which 
under these conditions triggers prolonged activation of STAT1, apoptosis and impaired 
in vivo growth.79 This strategy might be suitable in other conditions characterized by 
impaired STAT1 activation. 
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LEGEND TO FIGURE 1  
Balanced activation and opposite effects of STAT1 and STAT3 in tumour settings. 
Prevalent STAT3 activation and/or expression, often downstream of IL-6 production, 
favours tumour development and maintenance. Tumour cell proliferation and survival 
are favoured not only directly, but also indirectly by the maintainance of cancer stem 
cells and the switch to aerobic glycolysis. STAT3-dependent tumour-produced soluble 
factors such as IL-10 and VEGF induce STAT3-dependent tolerance in the immune 
cells. Moreover, STAT3 activation enhances metastasis formation by inducing EMT 
and cell migration and by increasing tumour angiogenesis. In contrast, the prevalence of 
STAT1 activation is fundamental to directly and indirectly block cell cycle progression 
and induce apoptosis of cancer cells. STAT1 elicits an efficient anti-tumour immune 
response both by stimulating antigen presentation to the immune system and by 
stimulating immune cells activity. CSCs, cancer stem cells; DC, dendritic cells; EMT, 
epithelial to mesenchymal transition (modified from ref. 2). 
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